The patient is still on combined treatment (ruxolitinib plus nilotinib) with DMR and good control of disease despite persistence of CALR mutation, 7 years after CML occurrence. This evidence concerns the gene CALR and chronic myelogenous leukemia, BCR-ABL1 positive.